[go: up one dir, main page]

DK1478394T3 - Stabiliseret TNFR-Fc formulation med arginin - Google Patents

Stabiliseret TNFR-Fc formulation med arginin

Info

Publication number
DK1478394T3
DK1478394T3 DK03716244T DK03716244T DK1478394T3 DK 1478394 T3 DK1478394 T3 DK 1478394T3 DK 03716244 T DK03716244 T DK 03716244T DK 03716244 T DK03716244 T DK 03716244T DK 1478394 T3 DK1478394 T3 DK 1478394T3
Authority
DK
Denmark
Prior art keywords
tnfr
arginine
stabilized
formulation
methods
Prior art date
Application number
DK03716244T
Other languages
English (en)
Inventor
Wayne R Gombotz
Richard L Remmele Jr
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27766211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1478394(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DK1478394T3 publication Critical patent/DK1478394T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK03716244T 2002-02-27 2003-02-27 Stabiliseret TNFR-Fc formulation med arginin DK1478394T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36025702P 2002-02-27 2002-02-27
PCT/US2003/006222 WO2003072060A2 (en) 2002-02-27 2003-02-27 Polypeptide formulation

Publications (1)

Publication Number Publication Date
DK1478394T3 true DK1478394T3 (da) 2008-10-13

Family

ID=27766211

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08006091.6T DK1946776T3 (da) 2002-02-27 2003-02-27 Stabiliseret tnfr-fc-sammensætning omfattende arginin
DK03716244T DK1478394T3 (da) 2002-02-27 2003-02-27 Stabiliseret TNFR-Fc formulation med arginin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08006091.6T DK1946776T3 (da) 2002-02-27 2003-02-27 Stabiliseret tnfr-fc-sammensætning omfattende arginin

Country Status (16)

Country Link
US (9) US20030180287A1 (da)
EP (1) EP1478394B1 (da)
JP (2) JP4583762B2 (da)
AT (1) ATE402716T1 (da)
AU (1) AU2003219958B2 (da)
CA (1) CA2476934C (da)
CY (1) CY1108361T1 (da)
DE (1) DE60322513D1 (da)
DK (2) DK1946776T3 (da)
ES (2) ES2311094T3 (da)
HU (1) HUE031630T2 (da)
MX (1) MXPA04008215A (da)
PL (1) PL215168B1 (da)
PT (2) PT1478394E (da)
SI (2) SI1478394T1 (da)
WO (1) WO2003072060A2 (da)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US7041196B2 (en) * 2003-02-06 2006-05-09 The Procter & Gamble Company Process for making a fibrous structure comprising cellulosic and synthetic fibers
RS51041B (sr) * 2003-02-28 2010-10-31 Ares Trading S.A. Tečne formulacije tbp-1 proteina koji vezuju faktor tumorske nekroze
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US20050037947A1 (en) * 2003-05-06 2005-02-17 Bitonti Alan J. Inhibition of drug binding to serum albumin
HUE026384T2 (en) * 2003-05-06 2016-06-28 Biogen Hemophilia Inc VII coagulation factor-FC chimeric proteins for the treatment of hemostasis disorder
US7507745B2 (en) 2004-02-20 2009-03-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins
US7655758B2 (en) * 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
ES2633574T3 (es) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
US7790679B2 (en) * 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
RU2008118166A (ru) * 2005-11-22 2009-12-27 Вайет (Us) Составы, содержащие гибридные белки, включающие иммуноглобулин
WO2007092772A2 (en) * 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
FR2899111B1 (fr) * 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament.
BRPI0710826A2 (pt) 2006-04-21 2011-08-23 Novartis Ag composições farmacêuticas de anticorpo anti-cd40 antagonista
PT2944306T (pt) 2006-06-16 2021-02-15 Regeneron Pharma Formulações antagonistas de vegf adequadas para administração intravitreal
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2099485B1 (en) * 2006-11-03 2018-03-21 AlphaVax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
GB0710321D0 (en) * 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
US20100189721A1 (en) * 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI543768B (zh) * 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
SG10201402265YA (en) * 2008-02-07 2014-08-28 Amgen Inc Stabilized protein compositions
EP2461679B1 (en) 2009-07-28 2019-02-13 GE Healthcare Bio-Sciences Corp. Vaccine stabilizer
CN102665691B (zh) * 2009-11-17 2015-05-27 益普生制药股份有限公司 hGH和rhIGF-1组合的制剂
US8887720B2 (en) 2010-04-26 2014-11-18 Geno Llc Delivery of ultra pure nitric oxide (NO)
CA2782320A1 (en) * 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life of fc fusion proteins
EP2523688B1 (en) 2010-01-15 2017-10-11 Kirin-Amgen, Inc. Antibody formulation and therapeutic regimens
EP2538973A2 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Stable antibody containing compositions
AU2011223710B2 (en) 2010-03-01 2016-04-14 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
EP2542221A4 (en) 2010-03-01 2013-10-23 Cytodyn Inc CONCENTRATED PROTEIN FORMULATIONS AND USES THEREOF
EP2563809B1 (en) 2010-04-27 2020-04-01 Scil Technology GmbH Stable aqueous mia/cd-rap formulations
WO2011141926A2 (en) 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
JP5919606B2 (ja) 2010-11-11 2016-05-18 アッヴィ バイオテクノロジー リミテッド 改良型高濃度抗ｔｎｆアルファ抗体液体製剤
CA2819333A1 (en) 2010-11-29 2012-06-07 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
US20120295911A1 (en) * 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
WO2012143418A1 (en) 2011-04-20 2012-10-26 Sandoz Ag STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
AU2012279205B2 (en) * 2011-07-01 2017-08-31 Biogen Ma Inc. Arginine - free TNFR : Fc- fusion polypeptide compositions and methods of use
EP2753634B1 (en) * 2011-08-17 2017-11-01 Ares Trading S.A. Method for preparing active form of tnfr-fc fusion protein
HK1200718A1 (en) 2011-10-18 2015-08-14 科荣生生物科学公司 Etanercept formulations stabilized with sodium chloride
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
HK1198689A1 (en) 2011-10-25 2015-05-29 Prothena Biosciences Limited Antibody formulations and methods
MY164611A (en) 2012-01-23 2018-01-30 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
CA2863944A1 (en) 2012-02-10 2013-08-15 Research Corporation Technologies, Inc. Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
MX363700B (es) * 2012-03-07 2019-03-29 Cadila Healthcare Ltd Formulaciones farmaceuticas de anticuerpos tnf-alfa.
WO2014011672A1 (en) * 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
SG11201501715QA (en) 2012-09-07 2015-05-28 Coherus Biosciences Inc Stable aqueous formulations of adalimumab
PE20150996A1 (es) * 2012-09-11 2015-08-01 Coherus Biosciences Inc Etanercept correctamente plegado de alta pureza y excelente rendimiento
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
ES2806946T3 (es) 2012-10-26 2021-02-19 Lupin Atlantis Holdings Sa Composición farmacéutica estable de la proteína de fusión TNFR:Fc etanercept
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
US9649383B2 (en) 2012-11-19 2017-05-16 Merck Sharp & Dohme Corp. Liquid formulations for TNFR:Fc fusion proteins
US9474803B2 (en) 2012-11-27 2016-10-25 Alteogen Inc. Composition for stabilizing fusion protein in which protein and FC domain are fused
HRP20181300T1 (hr) 2012-12-21 2018-10-05 Sanofi Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti
WO2014115882A1 (ja) 2013-01-28 2014-07-31 国立大学法人 熊本大学 タンパク質を安定化させたゲル状製剤
WO2014136113A1 (en) 2013-03-06 2014-09-12 Protalix Ltd. Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
CN105121460A (zh) 2013-03-06 2015-12-02 波塔力克斯有限公司 表达TNFα多肽抑制的植物细胞在治疗中的用途
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
CN105873601A (zh) * 2013-05-02 2016-08-17 马柏克辛斯公司 TNFR:Fc融合多肽的替代配方
AU2014314053C1 (en) 2013-08-30 2023-11-02 Takeda Pharmaceutical Company Limited Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
US10688187B2 (en) 2014-04-02 2020-06-23 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
CN106659785B (zh) 2014-05-07 2021-04-30 武田有限公司 包含gm-csf中和化合物的液体制剂
CN106536565A (zh) 2014-06-13 2017-03-22 鲁宾有限公司 一种用于纯化TNFR‑Fc融合蛋白的方法
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10000551B2 (en) 2014-09-11 2018-06-19 Protalix Ltd. Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
CN114569716A (zh) 2014-10-23 2022-06-03 美国安进公司 降低药物制剂的粘度
WO2016080367A1 (ja) 2014-11-18 2016-05-26 塩野義製薬株式会社 安定化されたペプチド組成物
WO2016102328A1 (en) 2014-12-22 2016-06-30 Ares Trading S.A. Liquid pharmaceutical composition
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US11154498B2 (en) * 2015-07-22 2021-10-26 Leiutis Pharmaceuticals Pvt. Ltd. Stabilized liquid formulation of levothyroxine
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
SG10202012778YA (en) * 2015-12-18 2021-01-28 Astellas Pharma Inc Pharmaceutical composition comprising anti-human tslp receptor antibody
US10695395B2 (en) * 2015-12-23 2020-06-30 Phoenix Tissue Repair, Inc. Collagen 7 compositions and methods of using the same
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
US11692027B2 (en) * 2016-09-28 2023-07-04 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
WO2018075818A1 (en) * 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
WO2018080196A2 (ko) 2016-10-28 2018-05-03 (주)셀트리온 안정한 약제학적 제제
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) * 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
WO2019094333A1 (en) * 2017-11-13 2019-05-16 Amgen Inc. Methods for producing protein products
MA50908A (fr) 2017-11-17 2020-09-23 Amgen Inc Formulations de protéines de fusion vegfr-fc
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
BR112020022610A2 (pt) 2018-05-10 2021-02-09 Regeneron Pharmaceuticals, Inc. proteína de fusão de receptor de vegf de alta concentração que contém formulações
TR201808283A2 (tr) * 2018-06-11 2018-07-23 Centurion Ilac San Ve Tic A S Sulu farmasöti̇k etenersept bi̇leşi̇mi̇
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
EP3810094A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3810268A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
GB201901547D0 (en) 2019-02-05 2019-03-27 Arecor Ltd Stabilized Fc Fusion protein solutions
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
IL303350A (en) * 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
MX2023006998A (es) 2020-12-22 2023-06-26 Amgen Inc Metodo de cultivo celular.
JP2024500994A (ja) 2020-12-28 2024-01-10 デボル，インコーポレイテッド タンパク質及び多官能化変性ポリエチレングリコール系架橋剤を含む反応性乾燥粉末状止血用材料
WO2022264097A1 (en) 2021-06-17 2022-12-22 Lupin Limited Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses
WO2023283049A1 (en) * 2021-07-09 2023-01-12 Macrogenics, Inc. Pharmaceutical compositions of a pd-1 antibody and use of the same
CN116643056B (zh) * 2022-02-15 2025-02-18 厦门万泰凯瑞生物技术有限公司 促甲状腺激素受体复合物、试剂盒、制备方法和用途
CN120548195A (zh) 2022-11-07 2025-08-26 上游生物公司 包含抗人类tslp受体抗体的药物组合物和其使用方法
KR20250115409A (ko) 2022-11-28 2025-07-30 암젠 인크 에타너셉트를 프로세싱하는 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4360457A (en) 1979-08-30 1982-11-23 Teijin Limited S-Sulfonated immunoglobulin composition having a high monomer content and a process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
WO1993007485A1 (en) * 1991-10-10 1993-04-15 The Regents Of The University Of California Rare immunoglobulin framework regions associated with human disease
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
CA2192821A1 (en) * 1994-06-24 1996-01-04 Wayne R. Gombotz Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US20030018025A1 (en) * 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO2001060397A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
HK1039065B (en) * 1999-04-08 2004-04-16 Genentech, Inc. Composition based on oppositely-charged polypeptides
CA2366785C (en) * 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
ATE464062T1 (de) * 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
NZ519222A (en) * 1999-12-14 2004-04-30 Genentech Inc TNF-alpha antagonists and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder
AU2262501A (en) * 1999-12-16 2001-06-25 Amgen, Inc. Tnfr/opg-like molecules and uses thereof
WO2001058473A1 (en) * 2000-02-10 2001-08-16 Wyeth Method of treating or inhibiting cellular injury or cell death
AU2002224555A1 (en) * 2000-07-25 2002-02-05 Takeda Chemical Industries Ltd. Process for producing recombinant protein
EP2311492B1 (en) * 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
US7943146B2 (en) * 2001-12-21 2011-05-17 Myrexis, Inc. Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface
WO2012143418A1 (en) 2011-04-20 2012-10-26 Sandoz Ag STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc

Also Published As

Publication number Publication date
EP1478394B1 (en) 2008-07-30
CA2476934C (en) 2009-06-16
US20070243185A1 (en) 2007-10-18
US20140377264A1 (en) 2014-12-25
EP1478394A4 (en) 2006-03-15
JP2005527503A (ja) 2005-09-15
US20030180287A1 (en) 2003-09-25
US20100086559A1 (en) 2010-04-08
MXPA04008215A (es) 2004-11-26
US9518111B2 (en) 2016-12-13
DE60322513D1 (de) 2008-09-11
US20190144523A1 (en) 2019-05-16
US11104714B2 (en) 2021-08-31
ATE402716T1 (de) 2008-08-15
US8119604B2 (en) 2012-02-21
SI1946776T1 (sl) 2017-07-31
JP2010106036A (ja) 2010-05-13
EP1478394A2 (en) 2004-11-24
US7648702B2 (en) 2010-01-19
DK1946776T3 (da) 2017-03-13
SI1478394T1 (sl) 2008-12-31
WO2003072060A2 (en) 2003-09-04
US20190292237A1 (en) 2019-09-26
US20120148587A1 (en) 2012-06-14
CA2476934A1 (en) 2003-09-04
PT1478394E (pt) 2008-10-08
US8828947B2 (en) 2014-09-09
US20170051039A1 (en) 2017-02-23
PT1946776T (pt) 2017-03-17
WO2003072060A3 (en) 2004-03-25
CY1108361T1 (el) 2014-02-12
US20220025016A1 (en) 2022-01-27
HUE031630T2 (en) 2017-07-28
ES2618832T3 (es) 2017-06-22
PL215168B1 (pl) 2013-10-31
PL374608A1 (en) 2005-10-31
ES2311094T3 (es) 2009-02-01
AU2003219958B2 (en) 2006-01-05
AU2003219958A1 (en) 2003-09-09
JP4583762B2 (ja) 2010-11-17

Similar Documents

Publication Publication Date Title
DK1478394T3 (da) Stabiliseret TNFR-Fc formulation med arginin
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
CY1110225T1 (el) Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης
CY1113312T1 (el) Κυκλικοι αναστολεις κινασης τυροσινης πρωτεϊνων
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
ATE509634T1 (de) Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
SG150550A1 (en) Pharmaceutical preparation containing an antibody for the egf receptor
DK1098649T3 (da) Fremgangsmåde til stabilisering af farmaceutiske sammensætninger med speciel anvendelse af antioxidant
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
NO20060023L (no) Fast preparat
BRPI0414593A (pt) derivados de ácido sulfonamida substituìda-indol-2-carboxìlico como inibidores de pai-1
WO2006033700A3 (en) Her2 antibody composition
ATE507822T1 (de) Stabilisierte zusammensetzungen von faktor-vii- polypeptiden
DE602005016532D1 (de) Pharmazeutische zusammensetzung mit einem benzodiaeins
DE602005015686D1 (de) Pharmazeutische zusammensetzung mit einem benzodiaeins
NO20050867L (no) Benzensulfonat av 4-fluor-2-cyano-pyrrolidinderivater
ATE468341T1 (de) Thienopyrazole
UY28897A1 (es) Ácido 2-((2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil)amino)-3-(fenilpiridin-2-ilamino)propiónico sustancialmente puro como inhibidor de la cinasa ikb
MXPA05011212A (es) Derivados de indeno como agentes farmaceuticos.
BR0302496A (pt) Composições farmacêuticas com atividade antibiótica
DE60224449D1 (de) Gebrauchsfertige paracetamol injektionslösungen enthaltend propylenglykol als einziges cosolvens
ATE259813T1 (de) Triazolopyrimidinderivate
BRPI0418726A (pt) naftalenossulfonato de clopidogrel cristalino ou hidrato do mesmo, método para sua preparação e composição farmacêutica contendo o mesmo
SV2006002220A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios ref. p-sv-78.836/cd
EP3782975A4 (en) COMPOUND WITH UNSATURATED DOUBLE BOND, OXYGEN ABSORBER SO AND RESIN COMPOSITION